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Abstract: Enhanced understanding of the rheumatoid arthritis (RA) pathophysiology and the 
role of cytokines has enabled the development of innovative biological agents in the last 10 years 
that target specific parts of the immune response. Failure to achieve adequate response with tra-
ditional disease modifying anti-rheumatic drugs (DMARDs) and increasing evidence of ongoing 
radiographic deterioration of the affected joints despite seemingly clinical response were essential 
stimuli for the development of biologics. The current and upcoming biological agents are primarily 
aimed at neutralizing circulating and cell-bound pro-inflammatory cytokines, interfering in the 
interaction of antigen-presenting and T-lymphocytes, eliminating circulating B-lymphocytes or 
by interfering with the intracellular signaling mechanisms of immuno-competent cells that lead to 
inflammation. These agents have improved the currently available treatments due to greater efficacy, 
fast action and greater tolerability. However, use of these agents has also been associated with 
significant, although rare, adverse events and considerable cost. Therefore, these agents should be 
used with caution by experienced clinicians. The present work aims to provide a global and updated 
review of the current and in-development biological DMARDs for the treatment of RA.
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Introduction
The introduction of biological agents has dramatically altered the therapy for patients 
with rheumatoid arthritis (RA). Advances in the current knowledge of cytokine 
milieu in RA pathogenesis have contributed to the development of biological agents, 
and translated research findings into clinical practice.
Well established currently available biological agents include three tumor necrosis 
factor alpha (TNF-α) inhibitors (infliximab, etanercept, adalimumab), an interleukin-1 
(IL-1) receptor antagonist (anakinra), a B-cell-depleting agent (rituximab), and an 
inhibitor of T-cell costimulation (abatacept). TNF inhibitors were the first biologics to be 
added to the therapeutic arsenal; more recently the US Food and Drug Administration 
(FDA) approved biologic agents with different modes of action. TNF inhibitors have 
proved to be very effective in patients not responding to traditional disease-modifying 
anti-rheumatic drugs (DMARDs). However, about 20% to 40% of patients treated 
with a TNF inhibitor fail to achieve a 20% improvement in American College of 
Rheumatology (ACR20) criteria, and more lose response over time, due to secondary 
failure or acquired therapeutic resistance and some experience adverse events following 
treatment with a TNF inhibitor.1 Two recently approved agents, certolizumab pegol and Biologics: Targets & Therapy 2009:3 444
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golimumab, have increased the number of available choices 
in the already existing class of TNF inhibitors.
Recently, several new agents have been reported to be in 
various stages of development and, if approved by regula-
tory authorities, may cause a major shift in the therapeutic 
paradigm of RA.
This paper provides a comprehensive review of the 
current and in-development biological DMARDS.
Methods
Information was derived from PubMed, and the clinical trials 
registered in Clinicaltrials.gov and database of systematic 
reviews and relevant congress abstracts up to and including 
May 2009. We systematically reviewed all the published and 
ongoing randomized controlled trials, to evaluate the efficacy, 
safety, and tolerability of the current and in-development 
biologics. Animal studies were excluded. The primary 
measure of outcome evaluated in most of the studies included 
improvement according to the ACR20 criteria, 28-joint 
Disease Activity Score (DAS28) score, Health Assessment 
Questionnaire (HAQ) score, and health related quality of life 
(HRQoL). Evidence of effectiveness has been summarized 
using the primary end points used in the studies identified. 
In addition, the most frequently reported adverse events have 
also been weighed against the benefits of the current and 
upcoming biologics.
No external sponsor was involved in this study. No 
persons other than the authors of this manuscript were 
involved in the design, analysis, and interpretation of data, 




Infliximab is a chimeric antibody that binds both transmem-
brane and circulating TNF-α. Its half-life of 8 to 10 days 
prompts its administration every 4 to 8 weeks at a dose of 
3 to 10 mg/kg infused intravenously. Based on the ATTRACT 
trial which included 428 patients resistant to MTX (MTX) 
with a mean disease duration of 11 years, infliximab proved 
to be beneficial when used in combination with MTX 
as it halted progression of joint damage both in clinical 
responders and non-responders. An obvious mechanism 
justifying the results is the hindering of TNF action on bone 
resorption and the blunting of TNF effect on synthesis of 
cartilage proteoglycan.2 Moreover, it was recently shown 
that impedance of joint damage in RA can also be attributed 
to infliximab’s effect on decreasing synovial infiltrates early 
after initiation of treatment by inhibiting cell migration and 
not by inducing apoptosis.3 Subgroup analysis of ATTRACT 
trial showed that radiographic stabilization of the disease 
was evident even in patients with early RA (ie, less than 
3 years).4,5 Furthermore, greater baseline joint damage 
correlated with poorer physical function at baseline and less 
improvement in physical function after treatment suggesting 
that early intervention may be required. This question was to 
be addressed by the ASPIRE trial that included 1004 patients 
with disease duration less than 3 years. Indeed, infliximab 
infusion along with MTX in a treatment naïve population 
improved clinical signs and symptoms, functional outcomes 
and prevented structural damage of the joints significantly 
more than MTX monotherapy.4
An important Dutch study (BeSt), examined the efficacy 
of initial combination therapy versus monotherapy, involving 
508 patients with newly diagnosed RA and comparing 
different treatment strategies. Sequential monotherapy 
(Group 1) and step-up combination therapy (Group 2), both 
starting with MTX, were compared with initial combination 
therapy consisting of a tapered high-dose prednisone, MTX, 
and sulfasalazine (SSA) (Group 3) and with initial combina-
tion therapy consisting of MTX and infliximab (Group 4). 
After 2 years of treatment, the goal of a DAS44 2.4 was 
reached by 82% in infliximab group comparing to 75% of 
patients in group 1, 81% in group 2, and 78% in group 3. 
More patients in combination groups 3 and 4 had been able 
to taper and discontinue drugs of the initial combination 
therapy because of continuous low disease activity, given 54% 
of patient receiving infliximab + MTX combination therapy 
tapered their treatment to monotherapy, compared to 36% 
in prednisone/MTX/SSA group. After 2 years of treatment, 
80% of all patients achieved the goal of DAS 2.4, and 42% 
reached clinical remission (DAS  1.6).6
Another randomized controlled trial (RCT) in 20 patients 
with poor prognosis RA identified by Persistent Inflamma-
tory Symmetrical Arthritis (PISA) score system and who 
had symptoms less than 1 year demonstrated a beneficial 
effect of infliximab and MTX introducing the concept of 
remission induction and maintenance therapy borrowed by 
oncology treatments.7 Furthermore, this study successfully 
demonstrated an arrest of the inflammatory bone loss in this 
patient population.8
Etanercept (Enbrel®)
Etanercept is a fully human, soluble fusion protein created 
by the linkage of two ligand binding regions of p75 TNF-α 
receptor and the Fc portion of human IgG1, and possess the Biologics: Targets & Therapy 2009:3 445
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shortest half life (3 to 4 days) of all the TNF-α inhibitors. 
Etanercept has unique properties that distinguish it from 
infliximab and adalimumab. In contrast to other anti-TNF 
agents, it also binds lymphotoxin-alpha (otherwise known 
as TNF-β) which has been associated with tumor growth 
control independent of TNF activity.9 In addition it does not 
lyse the cells expressing transmembrane TNF in the presence 
or absence of complement. Etanercept was approved by the 
FDA for use in the treatment of adult RA in 1998. Although 
frequently administered along with MTX in the clinical 
practice, etanercept has been approved as monotherapy and 
does not have to be co-administered with MTX.10
Moreland et al first evaluated the efficacy of etanercept 
monotherapy in a phase II RCT, recruiting 180 patients with 
refractory RA for 3 months. A dose dependent reduction in 
disease activity was seen, with 75% of the high dose group 
achieving ACR20 responses as compared to 14% in the 
placebo group.11 Subsequently, the results were confirmed by 
a phase III trial comparing two doses of etanercept (10 and 
25 mg sc, twice weekly). Both doses proved to be more 
effective than placebo and the 25 mg dose was more effective 
than the 10 mg dose.12
Combination of MTX and etanercept in active early RA 
(COMET) trial compared remission and radiographic non-
progression in patients treated with MTX monotherapy or 
with MTX plus etanercept. The observed analysis suggested 
50% of the patients on combination therapy with etaner-
cept and MTX successfully achieved clinical remission of 
the primary endpoint (DAS28 score) as compared to 28% 
taking MTX alone. Furthermore, the halting of radiographic 
progression was seen in 80% patients on combination therapy, 
compared to 59% patients taking MTX monotherapy.13
In one of the major biologic trials (TEMPO), a double 
blind, parallel-group, global study, 686 subjects were 
randomized to etanercept (25 mg twice weekly), MTX 
(up to 20 mg/week) or a combination of etanercept and 
MTX. Primary radiographic end point was change in the van 
der Heijde-modified total Sharp Score (TSS) at 52 weeks. 
Secondary radiographic endpoints were: changes in total 
erosions, changes in total joint space narrowing, number of 
eroded joints, non-progression (TSS change 0.5 and 3.0) 
and progression greater than the smallest detectable difference. 
Two observers, blinded for the sequence of the films, treat-
ment mode and patient identity scored each X-ray.
Results of the TEMPO trial demonstrated that 74.2% 
RA patients treated with etanercept plus MTX experi-
enced no progression of joint damage. In comparison, 
only 65.5% and 59.2% of etanercept monotherapy and 
MTX monotherapy-treated patients respectively, had no 
radiographic progression of joint damage at 2 years.14
Adalimumab (Humira®)
Adalimumab is a recombinant human IgG1 monoclonal 
antibody specific for human TNF-α. It not only inhibits 
the binding of TNF-α to its receptors, but also lyses cells 
expressing membrane bound TNF-α in the presence of 
complement. Adalimumab has an estimated half life of 
6 to 14 days and can be used as monotherapy or in combina-
tion with MTX for RA.10
These results are also supported by a prospective single-
arm intervention study, wherein 59 patients with established 
RA treated with fortnightly injections of subcutaneous 40 mg 
adalimumab for 6 months reported significant improvements 
in the following: perceived work ability [Work Ability Index 
(WAI)], quality of life [Rheumatoid Arthritis Quality of Life 
instrument (RAQoL)], and fatigue [Checklist Individual 
Strength (CIS)].15
A 2-year double-blind RCT (PREMIER) evaluated the 
efficacy of combination therapy of adalimumab plus MTX 
against MTX or adalimumab monotherapy in 799 patients 
with early active RA. Results after 1 year of therapy 
demonstrated achievement of ACR50 responses in 62% of 
patients treated with combination therapy as compared to 
46% and 41% of patients receiving MTX or adalimumab 
monotherapy respectively (P  0.001). Furthermore, after 
2 years of treatment, 49% of patients receiving combina-
tion therapy achieved disease remission (DAS28  2.6). 
Adalimumab in combination with MTX was also found to 
be more effective than either monotherapy in slowing the 
radiographic disease progression.16 The superior efficacy 
of adalimumab plus MTX over MTX monotherapy has also 
been demonstrated in a recent double-blind RCT in Taiwanese 
patients with active RA.17
The ARMADA trial, a 6 month placebo controlled, 
phase II/III study with 271 enrollees, demonstrated significant 
reductions in the signs and symptoms of RA, improvement 
in physical function, and the safety of adalimumab plus 
MTX vs placebo plus MTX. At 24 weeks, the combination 
treatment arm (adalimumab plus MTX) had significant 
higher ACR responses (ACR20: 67%, ACR50: 55%, and 
ACR70: 27%) compared with 15%, 8%, and 5%, respectively, 
in patients who had received placebo + MTX (P  0.001).18
In conclusion, adalimumab demonstrated significant and 
sustained reduction in signs and symptoms, inhibition of radio-
graphic progression, but and also improved functional status, 
quality of life and work productivity in patients with RA.Biologics: Targets & Therapy 2009:3 446
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Newly approved TNF-α inhibitors
Certolizumab pegol (Cimzia®)
Certolizumab is the first and only pegylated Fc-free anti-TNF 
agent which possesses a unique structure that does not 
include a crystallizable fragment (Fc) portion present in the 
other anti-TNFα agents, and have a unique way of signaling 
through the membrane TNF. Unlike other TNF-a inhibitors 
(infliximab, adalimumab, etanercept), which contain 
an Fc region, certolizumab is not capable of mediating 
antibody-dependent cell-mediated cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC).19
Efficacy in RA has been shown, when used as an 
add-on therapy to MTX, providing long-term improvement 
in physical function, HRQoL, and pain relief. It has been 
evaluated by two phase 3, double-blind RCTs.20,21 Smolen 
et al followed 619 patients for a period of 24 weeks and 
noticed that the patients in certolizumab pegol 200- and 
400-mg groups achieved ACR20 response rates of 57.3% 
and 57.6%, respectively vs 8.7% in placebo.20 Another 
double-blind RCT by Keystone et al recruited 982 patients for 
52 weeks, and showed that ACR20 response rates in groups 
receiving 200 mg and 400 mg of certolizumab pegol were 
58.8% and 60.8%, respectively, compared with 13.6% for 
placebo in patients who had previously failed to respond to 
MTX. The trial also showed that the drug had slowed mean 
radiographic progression from baseline by week 52, and 
improved physical function as early as week 1.21
Recently, the FAST4WARD study demonstrated the 
efficacy and safety of 400 mg certolizumab monotherapy 
given every 4 weeks, in 220 patients previously failing 1 
DMARD therapy. The ACR20 response rate achieved after 
24 weeks was 45.5% in certolizumab group as compared to 
9.3% in the placebo group (P  0.001). Other significant 
outcomes achieved during the study include ACR50, 
DAS28(ESR)3 scores.22
Although the efficacy profile of certolizumab appears to 
be at par with other TNF inhibitors, serious adverse events are 
not unusual, infections being the most frequent. Among the 
most frequent serious infectious adverse events were lower 
respiratory infection, gastroenteritis, urinary tract infections, 
and reactivation of tuberculosis.21
Golimumab (Simponi®)
Golimumab is similar in structure to infliximab except that 
it has been engineered to be fully human and is given in the 
dose of 50 mg as once-monthly subcutaneous injection.
The efficacy of golimumab has been evaluated through 
phase III clinical trials in the treatment of patients with 
active RA despite MTX therapy. Investigators observed; 
the patients receiving 100 mg golimumab + MTX or 50 mg 
golimumab + MTX achieved 56.2% and 55.1% ACR20 
response rates, respectively as compared to 44.4% in patients 
receiving 100 mg golimumab plus placebo.23 The addition 
of golimumab to MTX significantly reduced the signs and 
symptoms of RA and improved physical function.
The efficacy of golimumab plus MTX was confirmed in 
a multicenter, double-blind, placebo-controlled, dose-ranging 
RCT involving 172 patients who were randomly assigned to 
receive placebo plus MTX or 50 mg or 100 mg golimumab 
every 2 or 4 weeks plus MTX through week 48. At week 
16, 61% of patients in the combined golimumab plus MTX 
groups achieved ACR20 response as compared to 37% of 
patients in the placebo plus MTX group (P = 0.010) and 79% 
of patients in the group receiving 100 mg golimumab every 
2 weeks achieved ACR20 response (P = 0.001).24
Findings from 2 phase III clinical trials presented at the 
EULAR Annual Conference of Rheumatology provide data 
for the efficacy of golimumab in RA. The GO-AFTER trial 
evaluated the efficacy of golimumab in 461 patients with 
active RA, who were previously treated with TNF inhibitors, 
Table 1 TNF-α inhibitors in rheumatoid arthritis (RA)
First generation Newly approved
  Infliximab Etanercept Adalimumab Certolizumab Golimumab
Structure Mouse-human chimeric mab TNF-α receptor igG 
fusion protein
Fully human mab PeGylated Fc-free  
Fab´ mab
Fully human mab
Dose iv, 3–10 mg/kg q 4–8 weeks sc, 50 mg weekly sc, 40 mg q/o week sc, 400 mg q 2 weeks sc, 50 mg q 4 weeks
Half life 10 days 3 days 14 days 14 days ?
Side effects a a a a a
Stage of rA 
(early/late)
Both  Both  Both  Late rA  Late rA 
aCombined side effects of  TNF-α inhibitors include serious infections, opportunistic/invasive fungal infections, skin cancer, congestive heart failure, demyelination, HepB reactivation, 
lupus-like syndrome.
Abbreviations: iv, intravenous; sc, subcutaneous; q, every; q/o, every other.Biologics: Targets & Therapy 2009:3 447
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but where TNF inhibitors were discontinued due to lack of 
efficacy, intolerance or other reasons. At week 14, 35% and 
38% of patients receiving 50 mg and 100 mg golimumab, 
respectively, achieved the primary endpoint of ACR 20 
improvement compared with 18% of patients receiving 
placebo (P  0.001). At week 24, 52% of golimumab-treated 
patients experienced clinically relevant improvement (increase 
in HAQ score of at least 0.25 from baseline) compared with 
34% of placebo-treated patients (P  0.001). Also at week 24, 
patients receiving golimumab experienced a mean improve-
ment in HAQ of 0.27 ± 0.51, compared with an improvement 
of 0.05 ± 0.51 among patients receiving placebo (P  0.001). 
Importantly, among patients whose prior anti-TNF therapy 
was discontinued due to lack of efficacy, golimumab-treated 
patients experienced a mean improvement of 0.23 ± 0.50 in 
HAQ, compared with an average improvement of 0.06 ± 0.51 
for patients receiving placebo (P  0.05).25
In the GO-FORWARD trial, involving 444 patients, 50 mg 
and 100 mg monthly doses of golimumab were evaluated in 
patients who had active RA and were previously treated with 
MTX. Patients in the active treatment group achieved higher 
ACR 20 response at week 14 and significantly higher improve-
ment of physical function at week 24 (HAQ 0.46 ± 0.53 vs 
0.13 ± 0.58 [P  0.001]).25
The combination of golimumab and MTX appears to be 
generally well tolerated, with most adverse events ranging 
mild to moderate in severity. The most common adverse 
effects of golimumab therapy include nausea, headache and 
injection site reactions. Pneumonia was the most common 
serious adverse event observed in the patients receiving 
golimumab. Skin malignancy risk is elevated in golimumab-
treated patients, as is with other TNF inhibitors.24
The current data show that treatment with golimumab 
may induce an important depth of response, improving 
multiple aspects of RA and leading to significant decreases 
in disease activity. However, the efficacy of golimumab has 
not been tested against other TNF inhibitors in the existing 
studies. Thus, the appeal of golimumab in an already crowded 
arena will probably be as a self-injectable, fully humanized 
molecule given monthly. Notably, the currently approved 
dose in the US is 50 mg and, therefore, efficacy and safety 
data extrapolated from the clinical trials should correspond 
to this particular dose.
Safety and tolerability of  TNF inhibitors
TNF inhibitors have been indicated for the treatment of 
RA for more than 10 years and, as a result, they have a well 
established safety profile.
There is growing evidence that TNF inhibition is 
associated with serious infections, and clearly an impairment 
of host defense mechanism to fight gram-positive, gram-
negative bacteria, and less common pathogens causing 
opportunistic infections. Of particular concern are multiple 
reports of reactivation of Mycobacterium tuberculosis 
latent infections. Serious bacterial infections have been 
reported, including 2 fatal cases of pneumococcal sepsis and 
necrotizing fasciitis, and multiple cases of listeriosis (mostly 
with infliximab therapy).10
A number of studies have attempted to determine the 
incidence of tuberculosis in RA. As investigated in Korean 
population, the risk of tuberculosis was 8.9-fold higher for 
patients with RA and 30.1-fold higher for patients with RA 
treated with infliximab; etanercept use was not associated 
with any increased risk of tuberculosis above that seen in the 
general RA population.26 In lieu of these safety concerns, many 
experts recommend vigilant monitoring for the development 
of tuberculosis while on anti-TNF therapy and preventive 
measures. Evidence for an increased risk for serious infections 
and a dose dependent increase in malignancies was identified 
in systematic review and meta-analysis of nine randomized 
controlled trials of infliximab and adalimumab in patients 
with RA.27 Reports have also shown an increased mortality 
rate in RA patients with congestive heart failure NYHA III/IV 
treated with TNF inhibitors (especially infliximab).10,28
Evidence of invasive fungal infections (IFIs) also exists 
in association with the use of TNF inhibitors. As reported 
by Tsiodras et al, 80% of cases of IFIs were associated with 
infliximab, 16% with etanercept, and 4% with adalimumab; 
and the most prevalent IFIs identified were histoplasmosis 
(30%), candidiasis (23%), and aspergillosis (23%).29 The 
increased susceptibility to IFIs was thought to be attributed 
to the inhibition of IFN-γ production, decreased expression 
of pattern-recognition receptors, and leukocyte apoptosis.30 
Therefore a high index of suspicion and increased surveil-
lance of IFIs complicating TNF blockade is recommended 
because the course of such infections can be serious 
or fulminant, and rapid access to health care should be 
provided.
Recently Carter et al evaluated the safety profile of TNF 
inhibitors in pregnancy.31 Their report suggested that 59% of 
children born to mothers taking TNF inhibitors had one or 
more congenital anomalies that are part of vertebral abnor-
malities, anal atresia, cardiac defect, tracheoesophageal, 
renal, and limp abnormalities (VACTERL) association and 
the most common reported congenital anomaly was some 
form of heart defect. However, in an abstract presented at the Biologics: Targets & Therapy 2009:3 448
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2008 ACR scientific meeting, none of the fetuses exposed 
to infliximab in utero presented with VATER (VACTERL) 
malformations.32
Similarly, in another two 2008 ACR presentations on 
the pregnancy outcomes in women exposed to adalimumab 
(119 women) and etanercept (154 women) respectively, no 
concerns were raised regarding increased risks for specific 
pregnancy related outcomes.33,34
Ongoing registries, such as the one kept by the 
Organization of Teratology Information Specialists (OTIS), 
will be able to address the issue of safety in pregnancy more 
definitively in the near future. Certolizumab, one of the 
newer biologics, has the theoretical advantage of lacking 
an Fc portion, which is necessary for transport through the 
placenta, and it remains to be proven whether it may be safer 
for women trying to conceive.
TNF inhibitors have also been associated with the 
development of autoimmune diseases like systemic lupus 
erythematosis, lupus-like syndrome, cutaneous vasculitis, 
interstitial lung disease, and Behcet’s disease.35,36 Possible 
mechanisms that may induce antibody-production by TNF-α 
inhibitors include dysregulation of apoptosis with release 
of autoimmungenic plasma nucleosomes from apoptotic 
cells that trigger formation of autoantibodies against cyto-
plasmic and nuclear compounds or inhibition of a cytotoxic 
T lymphocyte response that normally suppresses autoreactive 
B cells.37 However, greater concentrations and frequencies 
of antinuclear, anticardiolipin and anti-dsDNA antibodies 
described with infliximab compared with etanercept or adali-
mumab suggest that factors other than TNF blockade may be 
responsible for induction of these autoimmune diseases.38,39
Because there may be a class effect, patients who fail treat-
ment with a TNF inhibitor because of a tolerability or safety 
issue may be at increased risk for a similar safety problem on 
an alternative TNF inhibitor. A UK-based study reported; the 
reasons for discontinuation of the switch-over (second) anti-
TNF-α agent were related to the reasons for stopping the first 
anti-TNF-α agent. Furthermore, the risk for developing an 
adverse event with a second TNF inhibitor increased 2-fold 
in patients switched because of an adverse event.40
Interleukin-1 receptor blocker
Anakinra (Kineret®)
Anakinra is recombinant, non-glycosylated form of IL-1 
receptor antagonist with half life of 4 to 6 hours and is admin-
istered as 100 mg subcutaneous daily injection. Presently, 
anakinra is the only IL-1 antagonist marketed and approved 
for the treatment of RA, alone or in combination with MTX. 
In Europe, this agent has been approved for the treatment of 
RA only in combination with MTX.
The efficacy of anakinra was evaluated as an add-on therapy 
in RA patients with inadequate response to monotherapy 
with non-biological DMARDS. Anakinra (100 mg, daily sc) 
was administered along with topical corticosteroid cream, 
despite patients on MTX (n = 48), leflunomide (n = 42), 
or cyclosporine-A (n = 32) treatment. At 48 weeks, the 
percentage of patients achieving ACR20, ACR50, and ACR70 
responses were 73%, 41%, and 23% respectively.41 Another 
pooled analysis of 5 clinical trials involving 2846 patients 
reported significant improvement of  ACR20 response in 
the participants treated with anakinra 50 to 150 mg daily vs 
placebo after 24 weeks (38% vs 23%). Significant improve-
ments were also observed with anakinra vs placebo in 
the following parameters: ACR50 (18% vs 7%), ACR70 
(7% vs 2%), HAQ score, visual analogue score for pain, 
Larsen radiographic scores, and ESR.42
Anakinra is fairly well tolerated, with injection-site 
reactions being the most common side effects, occurring in 
up to 70% of patients in dose-dependent manner.42–44 These 
reactions do not require treatment and can diminish with 
continued use. An increased incidence of serious infections 
was also noticed in anakinra treated patients, and the agent 
should be discontinued in the face of an active infection.45
The drug has been successfully used for many auto-
inflammatory syndromes.46 However, the use of anakinra 
for the treatment of RA has been limited worldwide due to 
its modest efficacy, especially when compared with the TNF 
inhibitors and the newer biologics. Although head-to-head 
comparison trials have not been carried out, the absolute 
improvement was less pronounced when compared to studies 
using other biological therapies. However, the recent develop-
ment of long-acting IL-1 inhibitors (rilonacept, canakinumab) 
for the auto-inflammatory syndromes, may provide us with 
new tools, if appropriate trials are ever conducted, to answer 
Table 2 Interleukin-1 (IL-1) receptor blockers in rheumatoid 
arthritis (RA)
  Anakinra AMG 108
Structure recombinant, non-glycosylated form of  
iL-1 receptor antagonist
–
Dose sc, 100 mg daily –
Half-life 4–6 hours –
Side effects injection site reactions, Serious infections –
Stage of rA 
(early/late)
Late rA  – 
Abbreviation: sc, subcutaneous.Biologics: Targets & Therapy 2009:3 449
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the question whether the lack of efficacy of anakinra lies 
within its mechanism of action (IL-1 inhibition) vs specific 




Tocilizumab, a new humanized, antihuman IL-6 receptor 
antibody with a number of randomized controlled trials 
evaluating its efficacy in RA, is now approved for the 
treatment of RA in Japan.47 Elevated levels of IL-6 in 
the serum and synovial fluid of RA patients contribute to 
the chronic inflammatory process characterizing RA and 
correlate positively with disease activity. Tocilizumab binds 
selectively and competitively to soluble and membrane-
expressed IL-6 receptors, blocking IL-6 signal transduction.48 
A number of trials in patients with early or long standing 
RA, have demonstrated the efficacy of intravenous tocili-
zumab 8 mg/kg every 4 weeks in improving disease activity, 
structural joint damage and/or HRQoL.49
Tocilizumab as monotherapy has shown efficacy in 
patients with an inadequate response to MTX therapy.50,51 
The AMBITION study randomized 673 patients with active 
RA to receive either tocilizumab or MTX for a period of 
24 weeks. Results demonstrated statistically significant 
improvement of the primary endpoint (ACR20) in patients 
treated with tocilizumab compared to MTX treatment 
(69.9% vs 52.5%, P  0.0001).50 The SATORI (Study of 
Active controlled TOcilizumab monotherapy for RA patients 
with an Inadequate response to MTX) study also demon-
strated superior efficacy among 80.3% of patients treated 
with 8 mg/kg of tocilizumab monotherapy every 4 weeks, 
achieving the primary endpoint (ACR20) at 24 weeks in 
comparison to 25% patients treated with 8 mg/week MTX 
therapy.51
The combination therapy of tocilizumab plus MTX 
was found to be more efficacious than tocilizumab mono-
therapy by various investigators. In a European study, 
researchers observed ACR20 response in 74% of patients 
receiving combination of 8 mg/kg tocilizumab plus MTX in 
comparison to 63% in patients receiving 8 mg/kg tocilizumab 
monotherapy. Additionally, statistically significant ACR50 
and ACR70 responses (P  0.05) were found in patients 
receiving the combination therapy.52
A study conducted by Emery et al demonstrated 
convincingly efficacy of tocilizumab plus MTX in RA 
patients with inadequate response to TNF inhibitors, a grow-
ing subpopulation of RA patients.53
As of safety profile, tocilizumab was well tolerated 
by adult patients with early and long-standing RA. Most 
frequently reported treatment-emergent adverse effects were 
mild to moderate in intensity, included upper respiratory tract 
infections, nasopharyngitis, headache, hypertension, and 
total cholesterol and ALT elevations.49 However, recently a 
study also identified marked suppression in the number of 
neutrophils in the peripheral blood of RA patients 1 day after 
the administration of tocilizumab, which may predispose to 
the development of infections, by adding an additional risk 
factor to an already underlying immunosuppressed state.54 
Further studies are being conducted to better define the safety 
profile of this agent.
In conclusion, intravenous tocilizumab is effective and 
generally well tolerated when administered either as mono-
therapy or in combination with conventional DMARDs in 
adult patients with moderate to severe active RA, regardless 
of disease duration or prior therapy.
B-cell depletion therapy
Rituximab (Rituxan®)
B-cell depletion using anti-CD20 antibodies is becoming a 
widely recognized therapeutic option for patients with severe 
RA, and currently rituximab is FDA approved in the United 
States for the treatment of RA in patients who have exhibited 
an inadequate response to or were intolerant to one or more 
TNF inhibitors in combination with MTX, on the basis of 
several randomized placebo-controlled studies.55–57
Rituximab is chimeric human/mouse anti-CD20 antibody, 
with plasma half life of 40 to 400 hours, and is administered 
in dose of two 1000 mg intravenous infusions separated by 
2 weeks. Rituximab induces a rapid depletion of normal 
CD20-expressing B-cells in the peripheral blood, and 
levels remain low or undetectable for 2 to 6 months before 
returning to pretreatment levels, generally within 12 months. 
Table 3 IL-6 receptor blocker (tocilizumab) in rheumatoid 
arthritis (RA)a
Structure Humanized anti-human iL-6 receptor Ab
Dose iv, 4–8 mg/kg body weight q 4 weeks
Half life 1.8–11.4 days at 4 mg/kg; 3.8–12.9 days at 8 mg/kg
Side effects Mild-moderate infections, hypertension, neutropenia,   
thrombocytopenia, hypercholesterolemia,   AST/ALT 
elevation
Stage of rA 
(early/late)
early and late rA 
aTocilizumab has been approved for treatment of rA in Japan.
Abbreviations: iL, interleukin; iv, intravenous; q, every.Biologics: Targets & Therapy 2009:3 450
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Serum immunoglobulin levels remain largely stable, although 
a reduction in IgM has been described.
The Randomised Evaluation oF Long-term Efficacy 
of rituXimab in RA (REFLEX) phase 3 study on 517 
RA patients showed that rituximab plus MTX treatment 
significantly reduced joint damage progression compared 
with placebo plus MTX. Significant reductions were 
observed from baseline to 56 weeks for rituximab plus 
MTX compared with placebo plus MTX in the following 
measures: Genant modified Sharp score (1.00 vs 2.31 
in placebo; P = 0.005), erosion score (0.59 versus 1.32; 
P = 0.011) and joint space narrowing score (0.41 vs 0.99; 
P  0.001).58 This difference is remarkable, given that the 
majority of patients in the placebo group (81%) received 
at least one course of rituximab, because from weeks 16 to 
24 patients who had failed to respond to treatment (20% 
improvement in swollen joint counts) could receive rescue 
therapy. In addition, rituximab has been shown to inhibit the 
radiographic progression independent of clinical response 
in such patient population.1
Results of an observational study in a population of 
patients with inadequate response to one or more TNF 
inhibitors indicated that rituximab may be more effective at 
controlling disease activity than switching to an alternative 
TNF inhibitor. Significant decrease in DAS 28 was reported 
in patients treated with rituximab (-1.61, 95% CI = -1.97 
to -1.25) than in those treated with an alternative TNF 
inhibitor (-0.98, 95% CI = -1.33 to -0.62) after 6 months of 
therapy.59 However, when the motive for interrupting TNF-α 
therapy was something other than ineffectiveness, both ritux-
imab and alternative TNF-α agents appear to offer similar 
levels of effectiveness, as shown in previous studies.40
Rituximab is by far the only agent that has formally 
demonstrated significant slowing of structural joint damage 
in RA patients with an inadequate response to or who 
are intolerant to TNF inhibitors. Although well known 
for its efficacy, rituximab can result in serious, including 
fatal infusion reactions, and rare progressive multifocal 
leukoencephalopathy (PML). PML has been well reported 
infectious complication occurring in patients with systemic 
lupus erythematosus (SLE). As reported by Molloy et al, 
nearly two thirds of cases of PML in patients with rheu-
matic diseases reported in the medical literature occurred 
in SLE patients.60 Twenty-three rituximab-treated oncology 
patients were reported by the FDA to have developed PML 
as of December 6, 2007. Most of these patients received 
rituximab in combination with chemotherapy or stem cell 
transplantation.61 However the occurrence of PML in RA 
patients has not been reported till date. Although the risk due to 
rituximab is difficult to assess given the multiple confounders, 
continued vigilance is warranted. Therefore the rheumatolo-
gists need to be vigilant and pursue the diagnosis of PML in 
all patients with unexplained neurological signs or symptoms 
with clinical and MRI findings compatible with the diagnosis. 
Once established, rituximab therapy should be discontinued; 
dose reductions and discontinuation should be considered 
for any concomitantly administered immunosuppressants. 
Additional concern that remains unaddressed is the number 
of rituximab infusions that can be safely administered.
Ocrelizumab
Ocrelizumab (OCR) is a novel anti-CD20 humanized mono-
clonal antibody, currently in clinical trials for the treatment 
of RA. In comparison with rituximab, ocrelizumab binds to a 
different, but overlapping, epitope of the extracellular domain 
of CD20 receptor. In vitro characterization of ocrelizumab 
demonstrated enhanced ADCC and reduced CDC compared 
with rituximab.62
Table 4 B-cell depleting agents (anti-CD20) in rheumatoid arthritis (RA)
Currently used In development
  Rituximab Ocrelizumab Ofatumumab TRU-015
Structure Chimeric human/mouse CD20  
agonist
Humanized (90%) CD20  
agonist
Fully human CD20 agonist  
(HuMax-CD20)
Human CD20 agonist with   
smaller mol structure
Dose iv, two 1000 mg infusion separated  
by 2 weeks
iv, two 200 mg infusions  
separated by 2 weeks
– –
Half-life 40–400 hours – – –
Side effects infusion reactions, infection risk,  
iGM decline, immunization
infusion reactions – –
Stage of rA 
(early/late)
Late rA  –  –  – 
Abbreviations: igM, immunoglobulin M; iv, intravenous.Biologics: Targets & Therapy 2009:3 451
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The ACTION trial (a randomized, placebo-controlled, 
blinded, phase I/II study of escalating doses of ocrelizumab 
in patients with moderate to severe RA on stable doses 
of concomitant MTX) investigated ocrelizumab across a 
wide range of doses in patients with moderate to severe 
RA receiving concomitant MTX therapy.62 A single course 
of ocrelizumab (2 infusions on days 1 and 15) at doses 
ranging from 10 to 1000 mg was administered. Clinical 
response was evaluated at 24 weeks and safety profile 
at 72 weeks of follow-up. A higher proportion of patients in 
all of the ocrelizumab groups achieved an ACR20, ACR50, 
or ACR70 response at week 24 as compared with patients 
in the placebo group. The ACR20 response rates at week 24 
were 42%, 35%, 45% and 50% in those receiving 10 mg, 
50 mg, 200 mg, and 500/1000 mg of OCR respectively. 
The ACR20 response rate in the placebo group was 22%.
The safety profile of ocrelizumab in this study was 
consistent across dosing groups and suggested only slight 
differences compared with placebo. The incidence of serious 
adverse events in the ocrelizumab-treated patients was 17.9% 
as compared with 14.6% in placebo group. The incidence 
of serious infections was 2.0% in all ocrelizumab treated 
patients and 4.9% in placebo-treated patients. All serious 
infections that were observed, resolved without sequelae.
Although ocrelizumab was well tolerated and appeared 
to be safe, additional experience with multiple trials will be 
required to validate the outcomes and further understand 
the clinical significance of human anti-human antibodies 
and potential advantages of this therapeutic approach 
over treatment with chimeric antibodies.
T -cell targeted therapy
Abatacept (Orencia®)
Abatacept is a fusion protein consisting of the human 
cytotoxic T-lymphocyte-associated antigen-4 molecule 
(CTLA-4) and immunoglobulin G1, both of which occur 
naturally in the body. By mimicking the actions of CTLA-4, 
abatacept inhibits one of the key costimulatory pathways 
(CD28:CD80/CD86) required for full T-cell activation.63 The 
drug has been approved for the treatment of RA patients who 
have exhibited an inadequate response to or were intolerant 
of one or more DMARDs or TNF inhibitors in the USA, or 
one or more TNF inhibitors only in Europe.1 Abatacept may 
be used either as a monotherapy or concomitantly only with 
DMARDs. As reported in the ASSURE (Abatacept Study 
of Safety in Use with other Rheumatoid arthritis therapies) 
trial, abatacept in combination with biologic background 
therapies was associated with an increased rate of serious 
adverse events.64 Therefore, abatacept is contra-indicated 
for concomitant use with TNF-α inhibitors, anakinra, and/or 
other biological therapies.
Several phase III trials have shown abatacept to be an 
effective option in patients who are refractory to TNF-α inhibi-
tion with impressive quality of life improvements. Two clinical 
trials evaluated the efficacy of abatacept for difficult-to-treat 
patients: the AIM for MTX-resistant cases and the ATTAIN 
for patients who are resistant to TNF-α inhibitors.65,66
A more recent randomized, double-blind placebo- and 
active (infliximab)-controlled, 12-month global trial known 
as ATTEST (for Abatacept or infliximab vs placebo, a Trial 
for Tolerability, Efficacy and Safety in Treating rheumatoid 
arthritis) suggested that standard weight-based abatacept 
might have comparable efficacy with a more favorable safety 
profile than infliximab 3 mg/kg.67 Trial was designed to 
obtain data on the magnitude of the treatment effect in RA 
of abatacept or infliximab (an established inhibitor of TNF 
for RA) vs placebo, and to obtain relative efficacy and safety 
data on these two biological treatments in a single study. The 
study utilized a double-blind, randomized, placebo-controlled 
design for the first 6 months to validate efficacy responses, 
and the study duration allowed for the opportunity to directly 
compare the safety profile of the active biologic treatment 
groups over 1 year.67
In this study, abatacept and infliximab (3 mg/kg every 
8 weeks) demonstrated similar efficacy. But overall, abata-
cept had a relatively more acceptable safety and tolerability 
profile, with fewer serious adverse events, serious infections, 
acute infusional events and discontinuations due to adverse 
events than the infliximab group. Limitations of the study 
were its short duration and the fact that the comparator 
(infliximab) dose was 3 mg/kg, the only approved dose at 
the time in the European Union.
Table 5 T-cell costimulation (abatacept)in rheumatoid arthritis (RA)
Structure 
 
Soluble fusion protein consisting of the extracellular 
domain of human CTLA4 and a fragment of the Fc 
portion of human IgG1 (hinge and CH2 and 3 domains)
Dose iv dose according to body weight (approximately 
10 mg/kg): 60 kg: 500 mg, 60–100 kg: 750 mg,  
100 kg: 1000 mg
Half life 13 days
Side effects Headache, increased infection risk, COPD exacerbation
Stage of rA 
(early/late)
early and Late rA 
Abbreviations: COPD, chronic obstructive pulmonary disease; Fc, crystallizable 
fragment; iv, intravenous.Biologics: Targets & Therapy 2009:3 452
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The efficacy of combined therapy, abatacept plus MTX 
have been confirmed by a 2-year follow-up study, where 80.3% 
of patients taking abatacept showed ACR20 improvement, 
30.9% achieved remission (CRP-DAS28  2.6) and 66.8% 
enhanced their physical function (as measured by the HAQ 
disability index). The mean changes in the physical and 
mental components summary scores of the Short-Form-36 
also confirmed a good improvement of HRQoL.68
The efficacy and safety of abatacept has also been 
evaluated in RA patients receiving etanercept. However, the 
percentage improvements in ACR20 response after 6 months 
of abatacept therapy were disappointing. Furthermore, after 
1 year of association of these two biologics, no notable 
changes in ACR responses were observed.69 Moreover this 
combination was shown to be linked to an increase in serious 
adverse events rate compared with patients receiving placebo 
and etanercept (16.5 vs 2.8%).
Unlike previous clinical trials enrolling patients with 
long-standing RA, Westhovens et al recently evaluated the 
efficacy of abatacept in MTX-naïve patients with early RA.70 
Abatacept study to Gauge Remission and joint damage 
progression in MTX-naïve patients with Early Erosive RA 
(AGREE) was a 2-year, double-blind trial that enrolled patients 
with less than 2 years of disease without MTX exposure 
(10 mg/week for 3). The study population of 509 patients 
was randomized to receive placebo plus MTX (increased up to 
20 mg/week) or abatacept 10 mg/kg plus MTX for 12-months 
before an open-label 12 month extension. The co-primary 
endpoints of the study were remission (DAS28  2.6) 
and Genant-modified Sharp total score. At year 1, 41.4% 
of abatacept-treated patients achieved remission as compared 
to 23.3% patients of placebo group. The proportion of patients 
with no radiographic progression was 61.2% and 52.9% in the 
abatacept and placebo-treated patients, respectively (difference 
of 8.3, 95% CI –1.0, 17.5). The change from baseline in 
total Genant-modified Sharp scores and erosion scores were 
significantly lower for abatacept, while minimal joint space 
narrowing progression was noted in both groups. Furthermore, 
71.9% of  abatacept-treated patients had clinically important 
improvement in the HAQ-DI compared to 62.1% in the 
placebo group (P = 0.024).
The safety profile of abatacept is comparable to that of 
other biologics. Severe infections were more common in 
abatacept-treated patients than in placebo-treated patients.71 
Opportunistic infections are rare in patients with abatacept 
and the frequency of malignancies, based on post-marketing 
surveillance and international patient cohorts, is not higher 
than expected in RA patients treated with DMARDS.72
Upcoming biological targets 
and therapies
Since substantial cross-talk between pro-inflammatory 
cytokines IL-1β, TNF-α, IL-6, and IL-17 is essential to 
induce joint destruction in RA,1 IL-1β and TNF-α promote 
IL-6 and tumor growth factor-beta (TGF-β) driven process 
of Th17 cell commitment and IL-17 production.73 Th17 cell 
polarization further induces IL-1β, TNF-α, IL-6, IL-8, and 
IL-17 production (Figure 1).74–77 Numerous studies have also 
demonstrated the critical role of B-cells in RA pathogenesis. 
A range of activated leukocyte cell types produce the TNF 
family B-cell pro-survival factors BLys (B-Lymphocyte 
stimulator) or BAFF (B-cell activation factor belonging 
to the TNF family) and APRIL (a proliferation inducing 
ligand).78,79 Levels of BAFF and APRIL are elevated in RA 
patients, with significantly higher levels in synovial fluid than 
in the serum.80,81 As illustrated in Figure 1, BLyS/BAFF binds 
3 receptors: BLyS receptor 3 (BR3, also termed BAFFR), 
transmembrane activator and calcium-signaling modulating 
and cyclophilin ligand (CAML) interactor (TACI), and B cell 
maturation antigen (BCMA) in contrast to APRIL, which 
selectively promote TACI and BCMA receptor-mediated 
NF-kβ signaling mechanisms.82
The following biological agents are being evaluated in 
ongoing trials (Figure 2 and Table 6):
a.  B-cell agents targeting CD20 (ocrelizumab, ofatumumab, 
and TRU-015), agents targeting cytokines important in 
the later stages of B cell maturation: BLyS or BAFF 
(belimumab, briobacept) and APRIL (atacicept), as well 
as other compounds targeting intracellular kinases 
Jak3 (CP 690,550) and Syk.
b.  T-cell agents targeting lymphotoxin beta (LTβ) and 
LIGHT (baminercept)
c.  Cytokine targeting agents: IL-1 (AMG 108), IL-6 
(tocilizumab), and IL-17A (AIN 457)
d.  Agents targeting osteoclasts via RANKL inhibition 
(denosumab)
Discussion
The following are unanswered questions on biological 
therapy in RA:
1.  Initiation of biologics: early or established RA?
2.  Can biomarkers guide initiation of biological therapy?
3.  Inter-class comparison of  existing and upcoming biologics: 
which and when to start?
4.  Need for a standard step-up/step-down therapy protocol 
for biologics: establishing a therapeutic algorithm 
for RA?Biologics: Targets & Therapy 2009:3 453
Biological targets in treatment of rheumatoid arthritis Dovepress



































Figure 1 Molecular targets of drugs in clinical trials for rheumatoid arthritis.
Abbreviations: APriL, a proliferation-inducing ligand; BCr, B-cell receptor; BLyS, B-lymphocyte stimulator; BAFF, B-cell activating factor; Br3, BLyS receptor 3; BCMA, B cell 
maturation antigen; HveM, herpes virus-entry mediator; iL, interleukin; LTβ, lymphotoxin beta; rANKL, receptor activator of nuclear factor kappa B ligand; TACi, transmembrane 
activator and CAML-interactor; TNF-α, tumor necrosis factor alpha.
Figure 2 Inflammatory cascade and molecular targets of current biologics in rheumatoid arthritis.
Abbreviations:  APC, antigen presenting cell; iL, interleukin; MHC, major histocompatibility complex; MMP, matrix metalloproteinase; NF-κβ, nuclear factor Kappa beta; 
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5.  Safety issues: Unique to an individual biologic agent or 
representative of a class effect?
6.  Ongoing vigilance: Is there a better way to monitor and 
record potential side effects of biologics identified after 
approval?
7.  Is it possible to discontinue biological therapy in patients 
achieving remission and, if so, when is the optimal 
timing?
8.  Perioperative infection risks while a patient on biological 
therapy: what is the timing of discontinuation of 
treatment/procedure/reinitiation of therapy? Need to 
readdress for every new biologic.
•  Biologics, usually in combination with traditional 
DMARDs such as MTX, have revolutionized the treatment 
of RA, producing significant improvement in clinical, 
radiographic and functional outcomes not seen previously. 
However, even with the availability of these medications, 
a significant proportion of patients either do not respond 
at all, or may respond initially and subsequently efficacy 
fades. Therefore, new agents, with different mechanisms 
of action, ie, targeting molecules involved in cellular 
interaction and/or signaling in immuno competent cells 
are being investigated through various clinical trials.
•  Results from existing RCTs are difficult to compare, 
because they involve different patient populations, study 
designs, and treatment strategies. Moreover there may 
be specific factors involving the different mechanisms 
and onset of action which may further complicate the 
comparison of different biological agents.
•  The key question of how to select the first/one particular 
biological agent to be given to a patient has been elegantly 
answered by Scott et al.83 The probable deciding factors 
explained include patient’s preference, relative efficacy, 
toxicity, and cost-effectiveness of different biologics. 
Different mechanisms of action might provide a theoretical 
rationale for the preference of one agent over another.
•  Targeting individual cytokines is a tried and successful 
approach in RA. However, careful consideration must 
be given not only to the cytokine targeted but also to the 
stage of the disease process being targeted. Furthermore, 
there is a lack of data, both on efficacy and safety, about 
the applicability of multiple cytokine inhibition.
•  Despite their clinical promises, monoclonal antibodies 
are raising concern about the potential adverse effects of 
long-term use. Published data currently do not exclude 
clinically important increased risks, nor do they refute 
beneficial effects. As per definition, much of the currently 
available safety data from trials or clinical practice do 
not capture the impact of any effects from sustained 
exposure to biologics. Additional studies are warranted 
to understand whether all these safety issues are unique 
to an individual biologic agent or representative of a class 
effect. Therefore, the treating physician must carefully 
weigh the benefits of these new biologics against their 
risks, particularly in frail patients at risk for infection.
Table 6 Biological agents in development for rheumatoid arthritisa
Cellular targets Biological agents Recent trials
  1.  iL-1 inhibitors AMG 108 Completed Phase ii
  2.  iL-6 inhibitors Tocilizumabb Phase iii
  3.  iL-17A inhibitors AiN 457 Phase i/ii






  5.    Cytokines in B-cell maturation
    a.  BLyS inhibitor







  6.  Jak3 inhibitors CP 690,550 Phase ii/iii
  7.  Syk inhibitors Tamatinib fosdium Phase ii
  8.  rANKL inhibitors Denosumab Phase ii
  9.    Lymphotoxin β and LiGHT pathway inhibitors Baminercept Phase ii
10.  p38 MAP inhibitors  vX 702 
SB-681323
Completed phase ii 
Phase i
aData collected from the registries on ClinicaTrials.gov until May 26, 2009.
bTocilizumab has been approved for treatment of rA in Japan.
Abbreviation: iL, interleukin.Biologics: Targets & Therapy 2009:3 455
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•  Although biologics have undisputed benefits in the 
treatment of RA, the cost issue remains unsolved. Costs 
are dramatically higher than for conventional medications, 
pharmacoeconomic concerns have been brought in the 
spotlight with their ever-expanding use. Across the board, 
the estimated yearly cost to use a biological agent is 
about US$20,000. The significant cost has to be balanced 
against the detrimental economic impact of RA on the 
individual patient and society as a whole. If biologics 
can prevent the morbidity, disability, and deterioration 
of the quality of life that RA often causes, then the use 
of a biological agent can be a cost-effective decision 
for societies. The development of biosimilar biologics, 
ie, generic medications that replicate the exact aminoacid 
structure of existing biologic DMARD molecules that 
lose their patent protection, may soon alter the landscape 
of biologics and its associated costs. However, biologics 
require a sophisticated manufacturing process, different 
from existing conventional medications and tight regula-
tion will be required to avoid possibly additional safety 
risks and make these agents truly cost-effective.
•  Several new therapies, currently in the pipeline, may 
soon be added to our already expanded number of treat-
ment options. Different types of RA patients will require 
different therapies, especially those who have failed 
multiple agents. These new options look promising in 
filling gaps in the treatment of RA patients. Comparative 
studies in sufficient numbers of patients should help shed 
more light on their exact role in RA treatment.
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